130 related articles for article (PubMed ID: 19617465)
21. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
23. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
24. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
[TBL] [Abstract][Full Text] [Related]
25. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
[TBL] [Abstract][Full Text] [Related]
26. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children and Young Adults With Recently Diagnosed Type 1 Diabetes.
Lee JB; Zhou W; Xu Z; Hedrick JA; Leu JH
J Clin Pharmacol; 2023 Jun; 63(6):721-731. PubMed ID: 36854991
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
31. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
[TBL] [Abstract][Full Text] [Related]
32. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
33. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
Vande Casteele N; Mould DR; Coarse J; Hasan I; Gils A; Feagan B; Sandborn WJ
Clin Pharmacokinet; 2017 Dec; 56(12):1513-1523. PubMed ID: 28353055
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis.
Takeuchi T; Chino Y; Mano Y; Kawanishi M; Sato Y; Uchida S; Tanaka Y
J Clin Pharmacol; 2024 Apr; 64(4):418-427. PubMed ID: 37909264
[TBL] [Abstract][Full Text] [Related]
35. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
36. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
37. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
Holman AJ; Ng E
Auton Neurosci; 2008 Dec; 143(1-2):58-67. PubMed ID: 18632310
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
39. The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy.
Vieira-Sousa E; Canhão H; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos F; Gomes JL; Aguiar R; Videira T; Pinto P; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Ribeiro RM; Fonseca JE
Acta Reumatol Port; 2018; 43(2):80-92. PubMed ID: 30091952
[TBL] [Abstract][Full Text] [Related]
40. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
